Chia-Pin Chang, The LEXI® cell isolation and enrichment is a process that isolates, identifies, and extracts target cells such as fetal cells from blood samples. ĭeveloped by INEX's Chief Technology Officer, Dr.
However, prevailing diagnostic procedures such as amniocentesis are invasive and carry a risk of pregnancy loss of up to approximately 5 per cent. LEXI® is a Non Invasive Prenatal Diagnostic (NIPD) technology that isolates fetal cells from the unborn baby, contained in the pregnant mother's blood for the definitive analysis of in excess of 7000 potential rare fetal genetic conditions.Ĭurrently, expectant mothers whose prenatal screening results show signs of fetal anomaly are often recommended to undergo prenatal diagnostic tests for a definitive diagnosis of fetal genetic abnormalities, as this allows for early medical treatment of these conditions. This initiative will tap on the research expertise of CUHK to further advance LEXI®, a novel fetal cell isolation technology developed by INEX Innovate. The CUHK Department of Obstetrics & Gynaecology (O&G) is world-renowned for its many prominent contributions and high-impact publications in the scientific community, attributed to its pursuit towards advancing the frontiers of knowledge in O&G through clinical, scientific and translational research. Richard Choy of The Chinese University of Hong Kong
0 kommentar(er)
